ArticleClinical rheumatology2026
Fatigue in primary and associated Sjögren's disease: similar burden, distinct determinants.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesFatigue is a disabling symptom in Sjögren's disease (SjD); however, its severity and related factors in associated SjD remain unclear. We compared fatigue severity among patients with primary Sjögren's disease (pSjD), associated SjD, and systemic autoimmune rheumatic diseases (SARDs) without SjD and identified fatigue-associated clinical and patient-reported factors in patients with pSjD and associated SjD.
methodsThis cross-sectional study included 115 patients with pSjD, 125 with associated SjD, and 52 with SARDs without SjD. Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). Clinical and laboratory parameters were analysed.
resultsFatigue was significantly more severe in pSjD and associated SjD than in SARDs without SjD (FACIT-F total: 30 vs. 36 vs. 42, p < 0.001), with no significant difference between pSjD and associated SjD. Patients with pSjD reported greater subjective symptom burden, including higher ESSPRI fatigue (7.0 vs. 5.0, p = 0.011) and dryness (7.0 vs. 5.0, p = 0.012) scores. In multivariate analysis, pain (pSjD: β -2.12, p < 0.001; associated SjD: β -0.79, p = 0.019) and dryness (pSjD: β -1.26, p = 0.002; associated SjD: β -2.07, p < 0.001) were independently related with fatigue in both groups. Fibromyalgia (β -15.4, p < 0.001) and arthritis (β -7.7, p = 0.006) were related only in pSjD, and C-reactive protein (β -1.53, p = 0.029) only in associated SjD. Fatigue was not linked with systemic disease activity (ESSDAI) in pSjD.
conclusionsFatigue is a major burden across the SjD spectrum, with similar severity in pSjD and associated SjD but distinct contributing mechanisms. Key Points • Fatigue severity was comparable between pSjD and associated SjD; however, distinct factors were associated with fatigue. • Fibromyalgia and arthritis were independently associated with fatigue in pSjD, whereas systemic inflammation contributed to associated SjD.
Indexed as
Identifiers
41775986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.